January 2022

Advisory Board Profile: Paul Carter

Part of what makes Chilam special is our ever-growing, star-studded board of advisors, a team of experienced industry leaders who share our vision for a better future for cannabis-based pharmaceuticals. Paul Carter, a key member of our advisory board, is no exception.

Paul brings an invaluable level of experience to the Chilam team with his robust background in the Biotech and Pharmaceutical industries. Paul is a seasoned executive with a proven track record of global leadership and accomplishment in the BioPharma world. Throughout his 30-year career in executive leadership, Paul has lived and worked extensively in the US, Europe, and Asia.

During his executive career, Paul served as Executive Vice-President and Chief Commercial Officer of Gilead Sciences Inc., where he was responsible for the company's worldwide commercial activity, including $33 billion of revenue in 2015 and launching several of the biggest selling prescription drugs of all time.

In 2016 Paul transitioned from his successful executive career into a portfolio of Board and Advisory roles. He is now contributing his experience, knowledge, and good judgment to a number of public and private companies, teams, and individuals throughout the world.

Paul has always had a passion for working in the Life Sciences industry and strives to keep technically and geographically relevant. He remains well connected to the industry through an always increasing global network of professional relationships in the life sciences space. Currently, he is a Board Director with four US-listed Biotech and Pharmaceutical companies as well as a retained advisor to several life-science focused businesses in the US, Europe, and China. This portfolio of advisor positions includes one in the digital space, and one being a leading European Private Equity firm. Paul is also the Chair of the Board of an early stage well funded private UK based Biotech company and Board Member respectively of a privately held market-leading Diagnostic company, a professional medical education business, and a consumer products company.